menu
    • menu
    [{"orgOrder":0,"company":"Arthrosi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"AR882","moa":"URAT1","graph1":"Nephrology","graph2":"Phase I","graph3":"Arthrosi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arthrosi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arthrosi Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Arthrosi Therapeutics","sponsor":"Guangrun Health Industry","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Series D Financing","leadProduct":"AR882","moa":"","graph1":"Rheumatology","graph2":"Phase II","graph3":"Arthrosi Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0.080000000000000002,"dosageForm":"Immediate Release Capsule","sponsorNew":"Arthrosi Therapeutics \/ Guangrun Health Industry","highestDevelopmentStatusID":"8","companyTruncated":"Arthrosi Therapeutics \/ Guangrun Health Industry"}]

    Find Clinical Drug Pipeline Developments & Deals by Arthrosi Therapeutics

    Menu

    Arthrosi Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Arthrosi Therapeutics

                            U.S.A arrow
                            Biotech Showcase
                            Not Confirmed

                            Arthrosi Therapeutics

                            U.S.A arrow
                            Biotech Showcase
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AR882

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase II

                            Sponsor : Guangrun Health Industry

                            Deal Size : $75.0 million

                            Deal Type : Series D Financing

                            DEALS_DEV arrow-down

                            Arthrosi Secures $75M in Series D Financing

                            Details : The company intends to use the net proceeds to fund the development of AR882, a highly potent and selective next-gen URAT1 inhibitor delivered in a once daily immediate release oral capsule, being developed for the treatment of gout.

                            Brand Name : AR882

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 12, 2023

                            Lead Product(s) : AR882

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase II

                            Sponsor : Guangrun Health Industry

                            Deal Size : $75.0 million

                            Deal Type : Series D Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Arthrosi Therapeutics

                            U.S.A arrow
                            Biotech Showcase
                            Not Confirmed

                            Arthrosi Therapeutics

                            U.S.A arrow
                            Biotech Showcase
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AR882

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Arthrosi Presents AR882 Posters at ACR 2021

                            Details : Company presented AR882, a potent and Selective Uricosuric agent, which have shown to be a promising new option for gout patients as a safe and potent urate lowering medication even in those with kidney impairment.

                            Brand Name : AR882

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 02, 2021

                            Lead Product(s) : AR882

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth